[1]
|
Prevalence of ABCC3
-1767G/A polymorphism among patients with antiretroviral-associated hepatotoxicity
Molecular Genetics & Genomic Medicine,
2020
DOI:10.1002/mgg3.1124
|
|
|
[2]
|
Prevalence of ABCC3‐1767G/A polymorphism among patients with antiretroviral‐associated hepatotoxicity
Molecular Genetics & Genomic Medicine,
2020
DOI:10.1002/mgg3.1124
|
|
|
[3]
|
A meta-analysis of MDR1 polymorphisms rs1128503 and rs1045642 and susceptibility to hepatocellular carcinoma
Journal of International Medical Research,
2019
DOI:10.1177/0300060519855869
|
|
|
[4]
|
Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study
Cancer Chemotherapy and Pharmacology,
2017
DOI:10.1007/s00280-017-3268-y
|
|
|
[5]
|
Genetic polymorphisms of the multidrug resistance 1 gene MDR1 and the risk of hepatocellular carcinoma
Tumor Biology,
2015
DOI:10.1007/s13277-015-3407-1
|
|
|
[6]
|
Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations
Liver International,
2014
DOI:10.1111/liv.12462
|
|
|
[7]
|
Targeted inhibition of the FGF19‐FGFR4 pathway in hepatocellular carcinoma; translational safety considerations
Liver International,
2014
DOI:10.1111/liv.12462
|
|
|
[8]
|
Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocellular carcinoma
Hepatology,
2013
DOI:10.1002/hep.26187
|
|
|